New efficacy signals are emerging for next-generation B-cell immune therapies, with one comparison study reporting survival benefit after anti-CD19 CAR T failure and another phase II result describing response patterns in low-blast myeloid cancers. A comparative analysis of the phase 2 BiCAR trial reported that a short ramp-up version of glofitamab significantly prolonged survival compared with contemporary non-bispecific salvage options after anti-CD19 CAR T-cell failure in diffuse large B-cell lymphoma. Separately, a phase II trial of CD123-targeting bispecific vibecotamab in low-blast myeloid cancers reported high response rates in myelodysplastic syndromes after hypomethylating agent failure, but with limited clearance in residual acute myeloid leukemia. Together, the findings reinforce that faster, delivery-optimized ramp schedules and CD123-directed bispecific designs are both being tested as routes to improve outcomes in populations where durability remains a central unmet need.